| GeneOntologyMolecularFunction | cysteine-type deubiquitinase activity | USP17L7 USP17L21 USP17L4 USP17L2 USP17L12 USP17L1 USP17L20 USP17L11 USP17L24 USP17L5 USP17L10 USP17L19 USP17L18 USP17L17 USP17L6P USP17L3 USP17L22 USP17L15 USP17L8 USP17L13 | 3.57e-26 | 114 | 96 | 20 | GO:0004843 |
| GeneOntologyMolecularFunction | deubiquitinase activity | USP17L7 USP17L21 USP17L4 USP17L2 USP17L12 USP17L1 USP17L20 USP17L11 USP17L24 USP17L5 USP17L10 USP17L19 USP17L18 USP17L17 USP17L6P USP17L3 USP17L22 USP17L15 USP17L8 USP17L13 | 2.15e-25 | 124 | 96 | 20 | GO:0101005 |
| GeneOntologyMolecularFunction | ubiquitin-like protein peptidase activity | USP17L7 USP17L21 USP17L4 USP17L2 USP17L12 USP17L1 USP17L20 USP17L11 USP17L24 USP17L5 USP17L10 USP17L19 USP17L18 USP17L17 USP17L6P USP17L3 USP17L22 USP17L15 USP17L8 USP17L13 | 1.77e-24 | 137 | 96 | 20 | GO:0019783 |
| GeneOntologyMolecularFunction | cysteine-type peptidase activity | USP17L7 USP17L21 USP17L4 USP17L2 USP17L12 USP17L1 USP17L20 USP17L11 USP17L24 USP17L5 USP17L10 USP17L19 CAPN10 USP17L18 USP17L17 USP17L6P USP17L3 USP17L22 USP17L15 USP17L8 USP17L13 | 6.02e-23 | 192 | 96 | 21 | GO:0008234 |
| GeneOntologyMolecularFunction | peptidase activity | USP17L7 USP17L21 USP17L4 USP17L2 USP17L12 USP17L1 USP17L20 USP17L11 USP17L24 USP17L5 USP17L10 USP17L19 CAPN10 USP17L18 DHH USP17L17 USP17L6P USP17L3 MMP1 MMP7 USP17L22 USP17L15 USP17L8 USP17L13 | 4.37e-15 | 654 | 96 | 24 | GO:0008233 |
| GeneOntologyMolecularFunction | hyaluronic acid binding | USP17L24 ACAN USP17L6P | 3.59e-04 | 29 | 96 | 3 | GO:0005540 |
| GeneOntologyBiologicalProcess | protein deubiquitination | USP17L7 USP17L21 USP17L4 USP17L2 USP17L12 USP17L1 USP17L20 USP17L11 USP17L24 USP17L5 USP17L10 USP17L19 USP17L18 USP17L17 USP17L6P USP17L3 USP17L22 USP17L15 USP17L8 USP17L13 | 8.52e-26 | 125 | 94 | 20 | GO:0016579 |
| GeneOntologyBiologicalProcess | protein modification by small protein removal | USP17L7 USP17L21 USP17L4 USP17L2 USP17L12 USP17L1 USP17L20 USP17L11 USP17L24 USP17L5 USP17L10 USP17L19 USP17L18 USP17L17 USP17L6P USP17L3 USP17L22 USP17L15 USP17L8 USP17L13 | 1.69e-24 | 144 | 94 | 20 | GO:0070646 |
| GeneOntologyBiologicalProcess | protein modification by small protein conjugation or removal | USP17L7 USP17L21 USP17L4 AMER1 USP17L2 USP17L12 USP17L1 USP17L20 USP17L11 USP17L24 USP17L5 USP17L10 USP17L19 USP17L18 RNF113B USP17L17 USP17L6P USP17L3 USP17L22 HERPUD1 USP17L15 USP17L8 USP17L13 | 1.01e-10 | 1009 | 94 | 23 | GO:0070647 |
| GeneOntologyBiologicalProcess | post-translational protein modification | USP17L7 USP17L21 USP17L4 AMER1 USP17L2 USP17L12 USP17L1 USP17L20 USP17L11 USP17L24 USP17L5 USP17L10 USP17L19 USP17L18 RNF113B USP17L17 USP17L6P USP17L3 USP17L22 HERPUD1 USP17L15 USP17L8 USP17L13 | 3.43e-10 | 1074 | 94 | 23 | GO:0043687 |
| GeneOntologyCellularComponent | endoplasmic reticulum membrane | USP17L7 USP17L21 USP17L4 USP17L2 USP17L12 USP17L1 USP17L20 USP17L11 USP17L5 USP17L10 USP17L19 USP17L18 DHH USP17L17 USP17L6P USP17L3 ATG9A USP17L22 HERPUD1 USP17L15 USP17L8 USP17L13 | 1.03e-07 | 1293 | 98 | 22 | GO:0005789 |
| GeneOntologyCellularComponent | endoplasmic reticulum subcompartment | USP17L7 USP17L21 USP17L4 USP17L2 USP17L12 USP17L1 USP17L20 USP17L11 USP17L5 USP17L10 USP17L19 USP17L18 DHH USP17L17 USP17L6P USP17L3 ATG9A USP17L22 HERPUD1 USP17L15 USP17L8 USP17L13 | 1.11e-07 | 1299 | 98 | 22 | GO:0098827 |
| GeneOntologyCellularComponent | nuclear outer membrane-endoplasmic reticulum membrane network | USP17L7 USP17L21 USP17L4 USP17L2 USP17L12 USP17L1 USP17L20 USP17L11 USP17L5 USP17L10 USP17L19 USP17L18 DHH USP17L17 USP17L6P USP17L3 ATG9A USP17L22 HERPUD1 USP17L15 USP17L8 USP17L13 | 1.61e-07 | 1327 | 98 | 22 | GO:0042175 |
| MousePheno | increased trophectoderm apoptosis | USP17L2 USP17L15 USP17L13 | 3.55e-06 | 8 | 57 | 3 | MP:0012119 |
| Domain | HABP4_PAI-RBP1 | USP17L7 USP17L21 USP17L2 USP17L12 USP17L20 USP17L11 USP17L24 USP17L5 USP17L19 USP17L18 USP17L17 USP17L3 USP17L22 USP17L13 | 2.46e-31 | 16 | 93 | 14 | PF04774 |
| Domain | HABP4_PAIRBP1-bd | USP17L7 USP17L21 USP17L2 USP17L12 USP17L20 USP17L11 USP17L24 USP17L5 USP17L19 USP17L18 USP17L17 USP17L3 USP17L22 USP17L13 | 2.46e-31 | 16 | 93 | 14 | IPR006861 |
| Domain | UCH | USP17L7 USP17L21 USP17L4 USP17L2 USP17L12 USP17L1 USP17L20 USP17L11 USP17L24 USP17L5 USP17L10 USP17L19 USP17L18 USP17L17 USP17L3 USP17L22 USP17L8 USP17L13 | 1.56e-26 | 71 | 93 | 18 | PF00443 |
| Domain | USP_2 | USP17L7 USP17L21 USP17L4 USP17L2 USP17L12 USP17L1 USP17L20 USP17L11 USP17L24 USP17L5 USP17L10 USP17L19 USP17L18 USP17L17 USP17L3 USP17L22 USP17L8 USP17L13 | 1.56e-26 | 71 | 93 | 18 | PS00973 |
| Domain | USP_3 | USP17L7 USP17L21 USP17L4 USP17L2 USP17L12 USP17L1 USP17L20 USP17L11 USP17L24 USP17L5 USP17L10 USP17L19 USP17L18 USP17L17 USP17L3 USP17L22 USP17L8 USP17L13 | 2.07e-26 | 72 | 93 | 18 | PS50235 |
| Domain | USP_dom | USP17L7 USP17L21 USP17L4 USP17L2 USP17L12 USP17L1 USP17L20 USP17L11 USP17L24 USP17L5 USP17L10 USP17L19 USP17L18 USP17L17 USP17L3 USP17L22 USP17L8 USP17L13 | 2.07e-26 | 72 | 93 | 18 | IPR028889 |
| Domain | Peptidase_C19_UCH | USP17L7 USP17L21 USP17L4 USP17L2 USP17L12 USP17L1 USP17L20 USP17L11 USP17L24 USP17L5 USP17L10 USP17L19 USP17L18 USP17L17 USP17L3 USP17L22 USP17L8 USP17L13 | 2.07e-26 | 72 | 93 | 18 | IPR001394 |
| Domain | USP_CS | USP17L7 USP17L21 USP17L2 USP17L12 USP17L1 USP17L20 USP17L11 USP17L24 USP17L5 USP17L10 USP17L19 USP17L18 USP17L17 USP17L3 USP17L22 USP17L8 USP17L13 | 3.14e-25 | 66 | 93 | 17 | IPR018200 |
| Domain | USP_1 | USP17L7 USP17L21 USP17L4 USP17L2 USP17L12 USP17L20 USP17L11 USP17L24 USP17L5 USP17L10 USP17L19 USP17L18 USP17L17 USP17L3 USP17L22 USP17L8 USP17L13 | 9.69e-25 | 70 | 93 | 17 | PS00972 |
| Domain | WD40 | GRWD1 DCAF8L2 DYNC2I1 BRWD3 LLGL2 LLGL1 WDR6 WDR87 TAF5 PHIP DYNC1I2 | 6.59e-08 | 259 | 93 | 11 | PF00400 |
| Domain | WD40 | GRWD1 DCAF8L2 DYNC2I1 BRWD3 LLGL2 LLGL1 WDR6 WDR87 TAF5 PHIP DYNC1I2 | 9.32e-08 | 268 | 93 | 11 | SM00320 |
| Domain | WD40_repeat | GRWD1 DCAF8L2 DYNC2I1 BRWD3 LLGL2 LLGL1 WDR6 WDR87 TAF5 PHIP DYNC1I2 | 1.08e-07 | 272 | 93 | 11 | IPR001680 |
| Domain | WD_REPEATS_2 | GRWD1 DCAF8L2 DYNC2I1 BRWD3 LLGL2 LLGL1 WDR6 WDR87 TAF5 PHIP DYNC1I2 | 1.40e-07 | 279 | 93 | 11 | PS50082 |
| Domain | WD_REPEATS_REGION | GRWD1 DCAF8L2 DYNC2I1 BRWD3 LLGL2 LLGL1 WDR6 WDR87 TAF5 PHIP DYNC1I2 | 1.40e-07 | 279 | 93 | 11 | PS50294 |
| Domain | WD40_repeat_dom | GRWD1 DCAF8L2 DYNC2I1 BRWD3 LLGL2 LLGL1 WDR6 WDR87 TAF5 PHIP DYNC1I2 | 2.62e-07 | 297 | 93 | 11 | IPR017986 |
| Domain | - | GRWD1 DCAF8L2 DYNC2I1 BRWD3 LLGL2 LLGL1 WDR6 WDR87 TAF5 PHIP DYNC1I2 | 8.13e-07 | 333 | 93 | 11 | 2.130.10.10 |
| Domain | WD40/YVTN_repeat-like_dom | GRWD1 DCAF8L2 DYNC2I1 BRWD3 LLGL2 LLGL1 WDR6 WDR87 TAF5 PHIP DYNC1I2 | 8.63e-07 | 335 | 93 | 11 | IPR015943 |
| Domain | WD_REPEATS_1 | GRWD1 DYNC2I1 BRWD3 LLGL2 LLGL1 WDR6 WDR87 TAF5 PHIP DYNC1I2 | 1.24e-06 | 278 | 93 | 10 | PS00678 |
| Domain | Quinoprotein_ADH-like_supfam | WDR6 WDR87 ARHGAP27 PHIP | 1.40e-04 | 53 | 93 | 4 | IPR011047 |
| Domain | LLGL | LLGL2 LLGL1 | 1.46e-04 | 4 | 93 | 2 | PF08366 |
| Domain | Lethal2_giant | LLGL2 LLGL1 | 1.46e-04 | 4 | 93 | 2 | IPR000664 |
| Domain | LLGL2 | LLGL2 LLGL1 | 1.46e-04 | 4 | 93 | 2 | IPR013577 |
| Domain | WD40_repeat_CS | GRWD1 BRWD3 LLGL2 LLGL1 TAF5 PHIP | 1.70e-04 | 164 | 93 | 6 | IPR019775 |
| Domain | BROMODOMAIN_1 | BRWD3 BRD7 PHIP | 8.21e-04 | 37 | 93 | 3 | PS00633 |
| Domain | VWC | MUC19 CCN4 CHRDL1 | 8.89e-04 | 38 | 93 | 3 | SM00214 |
| Domain | Bromodomain | BRWD3 BRD7 PHIP | 8.89e-04 | 38 | 93 | 3 | PF00439 |
| Domain | VWFC_2 | MUC19 CCN4 CHRDL1 | 8.89e-04 | 38 | 93 | 3 | PS50184 |
| Domain | BROMODOMAIN_2 | BRWD3 BRD7 PHIP | 1.11e-03 | 41 | 93 | 3 | PS50014 |
| Domain | BROMO | BRWD3 BRD7 PHIP | 1.19e-03 | 42 | 93 | 3 | SM00297 |
| Domain | Bromodomain | BRWD3 BRD7 PHIP | 1.19e-03 | 42 | 93 | 3 | IPR001487 |
| Domain | - | BRWD3 BRD7 PHIP | 1.19e-03 | 42 | 93 | 3 | 1.20.920.10 |
| Domain | VWF_dom | MUC19 CCN4 CHRDL1 | 1.19e-03 | 42 | 93 | 3 | IPR001007 |
| Domain | START | ACOT12 STARD9 | 2.47e-03 | 15 | 93 | 2 | PF01852 |
| Domain | Pept_M10A_Zn_BS | MMP1 MMP7 | 2.47e-03 | 15 | 93 | 2 | IPR021158 |
| Domain | START_lipid-bd_dom | ACOT12 STARD9 | 2.47e-03 | 15 | 93 | 2 | IPR002913 |
| Domain | START | ACOT12 STARD9 | 2.47e-03 | 15 | 93 | 2 | PS50848 |
| Domain | CTCK_1 | MUC19 CCN4 | 3.56e-03 | 18 | 93 | 2 | PS01185 |
| Domain | PG_binding_1 | MMP1 MMP7 | 4.40e-03 | 20 | 93 | 2 | PF01471 |
| Domain | Peptidoglycan-bd-like | MMP1 MMP7 | 4.40e-03 | 20 | 93 | 2 | IPR002477 |
| Domain | CT | MUC19 CCN4 | 5.31e-03 | 22 | 93 | 2 | SM00041 |
| Domain | Quino_amine_DH_bsu | BRWD3 WDR6 | 5.31e-03 | 22 | 93 | 2 | IPR011044 |
| Domain | - | HTR3E CHRNB2 | 5.80e-03 | 23 | 93 | 2 | 1.20.120.370 |
| Domain | M10A_MMP | MMP1 MMP7 | 5.80e-03 | 23 | 93 | 2 | IPR033739 |
| Domain | Acetylcholine_rcpt_TM | HTR3E CHRNB2 | 5.80e-03 | 23 | 93 | 2 | IPR027361 |
| Domain | - | ACOT12 STARD9 | 5.80e-03 | 23 | 93 | 2 | 3.30.530.20 |
| Domain | START-like_dom | ACOT12 STARD9 | 5.80e-03 | 23 | 93 | 2 | IPR023393 |
| Domain | Pept_M10A | MMP1 MMP7 | 5.80e-03 | 23 | 93 | 2 | IPR021190 |
| Pathway | REACTOME_RAS_PROCESSING | USP17L7 USP17L21 USP17L4 USP17L2 USP17L12 USP17L1 USP17L20 USP17L11 USP17L5 USP17L10 USP17L19 USP17L18 USP17L17 USP17L6P USP17L3 USP17L22 USP17L15 USP17L8 USP17L13 | 6.38e-33 | 45 | 73 | 19 | MM15671 |
| Pathway | REACTOME_UB_SPECIFIC_PROCESSING_PROTEASES | USP17L7 USP17L21 USP17L4 USP17L2 USP17L12 USP17L1 USP17L20 USP17L11 USP17L5 USP17L10 USP17L19 USP17L18 USP17L17 USP17L6P USP17L3 USP17L22 USP17L15 USP17L8 USP17L13 | 1.09e-19 | 191 | 73 | 19 | MM15289 |
| Pathway | REACTOME_UB_SPECIFIC_PROCESSING_PROTEASES | USP17L21 USP17L4 USP17L2 USP17L12 USP17L1 USP17L20 USP17L11 USP17L24 USP17L5 USP17L10 USP17L19 USP17L18 USP17L17 USP17L3 USP17L22 USP17L15 USP17L8 USP17L13 | 4.19e-17 | 221 | 73 | 18 | M27578 |
| Pathway | REACTOME_DEUBIQUITINATION | USP17L7 USP17L21 USP17L4 USP17L2 USP17L12 USP17L1 USP17L20 USP17L11 USP17L5 USP17L10 USP17L19 USP17L18 USP17L17 USP17L6P USP17L3 USP17L22 USP17L15 USP17L8 USP17L13 | 4.40e-17 | 262 | 73 | 19 | MM15286 |
| Pathway | REACTOME_MAPK_FAMILY_SIGNALING_CASCADES | USP17L7 USP17L21 USP17L4 USP17L2 USP17L12 USP17L1 USP17L20 USP17L11 USP17L5 USP17L10 USP17L19 USP17L18 USP17L17 USP17L6P USP17L3 USP17L22 USP17L15 USP17L8 USP17L13 | 1.60e-15 | 318 | 73 | 19 | MM15278 |
| Pathway | REACTOME_DEUBIQUITINATION | USP17L21 USP17L4 USP17L2 USP17L12 USP17L1 USP17L20 USP17L11 USP17L24 USP17L5 USP17L10 USP17L19 USP17L18 USP17L17 USP17L3 USP17L22 USP17L15 USP17L8 USP17L13 | 8.71e-15 | 299 | 73 | 18 | M27574 |
| Pathway | REACTOME_POST_TRANSLATIONAL_PROTEIN_MODIFICATION | USP17L7 FAM86B1 USP17L21 B3GNT9 USP17L4 USP17L2 USP17L12 USP17L1 USP17L20 USP17L11 MUC19 USP17L5 PEX13 USP17L10 USP17L19 CHGB USP17L18 FCSK USP17L17 USP17L6P USP17L3 CHRDL1 USP17L22 USP17L15 DYNC1I2 USP17L8 USP17L13 | 4.42e-10 | 1389 | 73 | 27 | MM15307 |
| Pathway | REACTOME_POST_TRANSLATIONAL_PROTEIN_MODIFICATION | USP17L21 B3GNT9 USP17L4 AMER1 USP17L2 USP17L12 USP17L1 USP17L20 USP17L11 USP17L24 USP17L5 PEX13 USP17L10 USP17L19 CHGB USP17L18 FCSK USP17L17 USP17L3 CHRDL1 USP17L22 USP17L15 DYNC1I2 USP17L8 USP17L13 | 4.07e-08 | 1475 | 73 | 25 | M19806 |
| Pubmed | DUB-1, a deubiquitinating enzyme with growth-suppressing activity. | USP17L7 USP17L21 USP17L4 USP17L2 USP17L12 USP17L1 USP17L20 USP17L11 USP17L5 USP17L10 USP17L19 USP17L18 USP17L17 USP17L6P USP17L3 USP17L22 USP17L15 USP17L8 USP17L13 | 1.42e-47 | 21 | 99 | 19 | 8622927 |
| Pubmed | DUB-1A, a novel deubiquitinating enzyme subfamily member, is polyubiquitinated and cytokine-inducible in B-lymphocytes. | USP17L7 USP17L21 USP17L4 USP17L2 USP17L12 USP17L1 USP17L20 USP17L11 USP17L5 USP17L10 USP17L19 USP17L18 USP17L17 USP17L6P USP17L3 USP17L22 USP17L15 USP17L8 USP17L13 | 1.42e-47 | 21 | 99 | 19 | 14583620 |
| Pubmed | DUB-2A, a new member of the DUB subfamily of hematopoietic deubiquitinating enzymes. | USP17L7 USP17L21 USP17L4 USP17L2 USP17L12 USP17L1 USP17L20 USP17L11 USP17L5 USP17L10 USP17L19 USP17L18 USP17L17 USP17L6P USP17L3 USP17L22 USP17L15 USP17L8 USP17L13 | 1.42e-47 | 21 | 99 | 19 | 11468161 |
| Pubmed | The murine DUB-1 gene is specifically induced by the betac subunit of interleukin-3 receptor. | USP17L7 USP17L21 USP17L4 USP17L2 USP17L12 USP17L1 USP17L20 USP17L11 USP17L5 USP17L10 USP17L19 USP17L18 USP17L17 USP17L6P USP17L3 USP17L22 USP17L15 USP17L8 USP17L13 | 1.42e-47 | 21 | 99 | 19 | 8756639 |
| Pubmed | Lymphocyte-specific murine deubiquitinating enzymes induced by cytokines. | USP17L7 USP17L21 USP17L4 USP17L2 USP17L12 USP17L1 USP17L20 USP17L11 USP17L5 USP17L10 USP17L19 USP17L18 USP17L17 USP17L6P USP17L3 USP17L22 USP17L15 USP17L8 USP17L13 | 1.42e-47 | 21 | 99 | 19 | 12447969 |
| Pubmed | DUB-1, a fate determinant of dynein heavy chain in B-lymphocytes, is regulated by the ubiquitin-proteasome pathway. | USP17L7 USP17L21 USP17L4 USP17L2 USP17L12 USP17L1 USP17L20 USP17L11 USP17L5 USP17L10 USP17L19 USP17L18 USP17L17 USP17L6P USP17L3 USP17L22 USP17L15 USP17L8 USP17L13 | 1.42e-47 | 21 | 99 | 19 | 18980247 |
| Pubmed | JAK2 is required for induction of the murine DUB-1 gene. | USP17L7 USP17L21 USP17L4 USP17L2 USP17L12 USP17L1 USP17L20 USP17L11 USP17L5 USP17L10 USP17L19 USP17L18 USP17L17 USP17L6P USP17L3 USP17L22 USP17L15 USP17L8 USP17L13 | 1.04e-46 | 22 | 99 | 19 | 9154835 |
| Pubmed | DUB-2 is a member of a novel family of cytokine-inducible deubiquitinating enzymes. | USP17L7 USP17L21 USP17L4 USP17L2 USP17L12 USP17L1 USP17L20 USP17L11 USP17L5 USP17L10 USP17L19 USP17L18 USP17L17 USP17L6P USP17L3 USP17L22 USP17L15 USP17L8 USP17L13 | 2.86e-45 | 24 | 99 | 19 | 8995226 |
| Pubmed | Interleukin 1 receptor signaling regulates DUBA expression and facilitates Toll-like receptor 9-driven antiinflammatory cytokine production. | USP17L7 USP17L21 USP17L4 USP17L2 USP17L12 USP17L1 USP17L20 USP17L11 USP17L5 USP17L10 USP17L19 USP17L18 USP17L17 USP17L6P USP17L3 USP17L22 USP17L15 USP17L8 USP17L13 | 1.19e-44 | 25 | 99 | 19 | 21115691 |
| Pubmed | Decabromodiphenyl ethane affects embryonic development by interfering with nuclear F-actin in zygotes and leads to cognitive and social disorders in offspring mice. | USP17L7 USP17L21 USP17L4 USP17L2 USP17L12 USP17L1 USP17L20 USP17L11 USP17L5 USP17L10 USP17L19 USP17L18 USP17L17 USP17L6P USP17L3 USP17L22 USP17L15 USP17L8 USP17L13 | 4.40e-44 | 26 | 99 | 19 | 35816173 |
| Pubmed | Cdc25A and Dub3 in a high-stakes balancing act. | USP17L7 USP17L21 USP17L4 USP17L2 USP17L12 USP17L1 USP17L20 USP17L11 USP17L24 USP17L5 USP17L10 USP17L19 USP17L18 USP17L17 USP17L6P USP17L3 USP17L22 USP17L15 USP17L8 USP17L13 | 8.72e-44 | 33 | 99 | 20 | 20228807 |
| Pubmed | The DUB/USP17 deubiquitinating enzymes: a gene family within a tandemly repeated sequence, is also embedded within the copy number variable beta-defensin cluster. | USP17L7 USP17L21 USP17L4 USP17L2 USP17L12 USP17L1 USP17L20 USP17L11 USP17L24 USP17L5 USP17L10 USP17L19 USP17L18 USP17L17 USP17L6P USP17L3 USP17L22 USP17L15 USP17L8 USP17L13 | 2.11e-43 | 34 | 99 | 20 | 20403174 |
| Pubmed | Hyaluronan- and RNA-binding deubiquitinating enzymes of USP17 family members associated with cell viability. | USP17L7 USP17L21 USP17L4 USP17L2 USP17L12 USP17L1 USP17L20 USP17L11 USP17L24 USP17L5 USP17L10 USP17L19 USP17L18 USP17L17 USP17L6P USP17L3 USP17L22 USP17L15 USP17L8 USP17L13 | 2.11e-43 | 34 | 99 | 20 | 17109758 |
| Pubmed | The deubiquitinating enzyme USP17 is highly expressed in tumor biopsies, is cell cycle regulated, and is required for G1-S progression. | USP17L7 USP17L21 USP17L4 USP17L2 USP17L12 USP17L1 USP17L20 USP17L11 USP17L24 USP17L5 USP17L10 USP17L19 USP17L18 USP17L17 USP17L6P USP17L3 USP17L22 USP17L15 USP17L8 USP17L13 | 2.11e-43 | 34 | 99 | 20 | 20388806 |
| Pubmed | DUB-3, a cytokine-inducible deubiquitinating enzyme that blocks proliferation. | USP17L7 USP17L21 USP17L4 USP17L2 USP17L12 USP17L1 USP17L20 USP17L11 USP17L24 USP17L5 USP17L10 USP17L19 USP17L18 USP17L17 USP17L6P USP17L3 USP17L22 USP17L15 USP17L8 USP17L13 | 2.11e-43 | 34 | 99 | 20 | 14699124 |
| Pubmed | Polyclonal and monoclonal antibodies specific for USP17, a proapoptotic deubiquitinating enzyme. | USP17L7 USP17L21 USP17L4 USP17L2 USP17L12 USP17L1 USP17L20 USP17L11 USP17L24 USP17L5 USP17L10 USP17L19 USP17L18 USP17L17 USP17L6P USP17L3 USP17L22 USP17L15 USP17L8 USP17L13 | 2.11e-43 | 34 | 99 | 20 | 20715989 |
| Pubmed | Human megasatellite DNA RS447: copy-number polymorphisms and interspecies conservation. | USP17L7 USP17L21 USP17L4 USP17L2 USP17L12 USP17L1 USP17L20 USP17L11 USP17L24 USP17L5 USP17L10 USP17L19 USP17L18 USP17L17 USP17L6P USP17L3 USP17L22 USP17L15 USP17L8 USP17L13 | 2.11e-43 | 34 | 99 | 20 | 9806828 |
| Pubmed | The ubiquitin-specific protease 17 is involved in virus-triggered type I IFN signaling. | USP17L7 USP17L21 USP17L4 USP17L2 USP17L12 USP17L1 USP17L20 USP17L11 USP17L24 USP17L5 USP17L10 USP17L19 USP17L18 USP17L17 USP17L6P USP17L3 USP17L22 USP17L15 USP17L8 USP17L13 | 2.11e-43 | 34 | 99 | 20 | 20368735 |
| Pubmed | The DUB/USP17 deubiquitinating enzymes, a multigene family within a tandemly repeated sequence. | USP17L7 USP17L21 USP17L4 USP17L2 USP17L12 USP17L1 USP17L20 USP17L11 USP17L24 USP17L5 USP17L10 USP17L19 USP17L18 USP17L17 USP17L6P USP17L3 USP17L22 USP17L15 USP17L8 USP17L13 | 2.11e-43 | 34 | 99 | 20 | 15780755 |
| Pubmed | USP17 regulates Ras activation and cell proliferation by blocking RCE1 activity. | USP17L7 USP17L21 USP17L4 USP17L2 USP17L12 USP17L1 USP17L20 USP17L11 USP17L24 USP17L5 USP17L10 USP17L19 USP17L18 USP17L17 USP17L6P USP17L3 USP17L22 USP17L15 USP17L8 USP17L13 | 2.11e-43 | 34 | 99 | 20 | 19188362 |
| Pubmed | Unstable transmission of the RS447 human megasatellite tandem repetitive sequence that contains the USP17 deubiquitinating enzyme gene. | USP17L7 USP17L21 USP17L4 USP17L2 USP17L12 USP17L1 USP17L20 USP17L11 USP17L24 USP17L5 USP17L10 USP17L19 USP17L18 USP17L17 USP17L6P USP17L3 USP17L22 USP17L15 USP17L8 USP17L13 | 2.11e-43 | 34 | 99 | 20 | 11941478 |
| Pubmed | The RS447 human megasatellite tandem repetitive sequence encodes a novel deubiquitinating enzyme with a functional promoter. | USP17L7 USP17L21 USP17L4 USP17L2 USP17L12 USP17L1 USP17L20 USP17L11 USP17L24 USP17L5 USP17L10 USP17L19 USP17L18 USP17L17 USP17L6P USP17L3 USP17L22 USP17L15 USP17L8 USP17L13 | 2.11e-43 | 34 | 99 | 20 | 10936051 |
| Pubmed | The deubiquitinating enzyme USP17 is essential for GTPase subcellular localization and cell motility. | USP17L7 USP17L21 USP17L4 USP17L2 USP17L12 USP17L1 USP17L20 USP17L11 USP17L24 USP17L5 USP17L10 USP17L19 USP17L18 USP17L17 USP17L6P USP17L3 USP17L22 USP17L15 USP17L8 USP17L13 | 2.11e-43 | 34 | 99 | 20 | 21448158 |
| Pubmed | Cytokine-regulated protein degradation by the ubiquitination system. | USP17L7 USP17L21 USP17L4 USP17L2 USP17L12 USP17L1 USP17L20 USP17L11 USP17L24 USP17L5 USP17L10 USP17L19 USP17L18 USP17L17 USP17L6P USP17L3 USP17L22 USP17L15 USP17L8 USP17L13 | 4.92e-43 | 35 | 99 | 20 | 16611142 |
| Pubmed | Lys-63-specific deubiquitination of SDS3 by USP17 regulates HDAC activity. | USP17L7 USP17L21 USP17L4 USP17L2 USP17L12 USP17L1 USP17L20 USP17L11 USP17L24 USP17L5 USP17L10 USP17L19 USP17L18 USP17L17 USP17L6P USP17L3 USP17L22 USP17L15 USP17L8 USP17L13 | 4.92e-43 | 35 | 99 | 20 | 21239494 |
| Pubmed | The deubiquitinating enzyme USP17 blocks N-Ras membrane trafficking and activation but leaves K-Ras unaffected. | USP17L7 USP17L21 USP17L4 USP17L2 USP17L12 USP17L1 USP17L20 USP17L11 USP17L24 USP17L5 USP17L10 USP17L19 USP17L18 USP17L17 USP17L6P USP17L3 USP17L22 USP17L15 USP17L8 USP17L13 | 1.10e-42 | 36 | 99 | 20 | 20147298 |
| Pubmed | Minor Splicing Factors Zrsr1 and Zrsr2 Are Essential for Early Embryo Development and 2-Cell-Like Conversion. | USP17L7 USP17L21 USP17L4 USP17L2 USP17L12 USP17L1 USP17L20 USP17L11 USP17L5 USP17L10 USP17L19 USP17L18 USP17L17 USP17L6P USP17L3 USP17L22 USP17L15 USP17L8 USP17L13 | 1.33e-42 | 29 | 99 | 19 | 32527007 |
| Pubmed | Ubiquitin hydrolase Dub3 promotes oncogenic transformation by stabilizing Cdc25A. | USP17L7 USP17L21 USP17L4 USP17L2 USP17L12 USP17L1 USP17L20 USP17L11 USP17L24 USP17L5 USP17L10 USP17L19 USP17L18 USP17L17 USP17L6P USP17L3 USP17L22 USP17L15 USP17L8 USP17L13 | 2.40e-42 | 37 | 99 | 20 | 20228808 |
| Pubmed | DUX is a non-essential synchronizer of zygotic genome activation. | USP17L7 USP17L21 USP17L4 USP17L2 USP17L12 USP17L1 USP17L20 USP17L11 USP17L5 USP17L10 USP17L19 USP17L18 USP17L17 USP17L6P USP17L3 USP17L22 USP17L15 USP17L8 USP17L13 | 1.93e-36 | 50 | 99 | 19 | 31806660 |
| Pubmed | High Dub3 expression in mouse ESCs couples the G1/S checkpoint to pluripotency. | USP17L7 USP17L4 USP17L2 USP17L1 USP17L6P USP17L3 USP17L15 USP17L8 | 1.45e-19 | 10 | 99 | 8 | 24207026 |
| Pubmed | Cell cycle-dependent expression of Dub3, Nanog and the p160 family of nuclear receptor coactivators (NCoAs) in mouse embryonic stem cells. | USP17L7 USP17L4 USP17L2 USP17L1 USP17L6P USP17L3 USP17L15 USP17L8 | 1.58e-18 | 12 | 99 | 8 | 24695638 |
| Pubmed | ES cell neural differentiation reveals a substantial number of novel ESTs. | USP17L7 USP17L4 USP17L2 USP17L1 USP17L6P USP17L3 USP17L15 USP17L8 | 9.56e-18 | 14 | 99 | 8 | 11793228 |
| Pubmed | CDK4/6-dependent activation of DUB3 regulates cancer metastasis through SNAIL1. | USP17L7 USP17L4 USP17L2 USP17L1 USP17L6P USP17L3 USP17L15 USP17L8 | 2.38e-16 | 19 | 99 | 8 | 28067227 |
| Pubmed | USP7 represses lineage differentiation genes in mouse embryonic stem cells by both catalytic and noncatalytic activities. | USP17L7 USP17L21 USP17L4 AMER1 USP17L2 USP17L12 USP17L1 USP17L20 USP17L11 USP17L5 USP17L10 USP17L19 USP17L18 RNF113B USP17L17 USP17L6P USP17L3 USP17L22 USP17L15 USP17L8 USP17L13 | 3.13e-16 | 674 | 99 | 21 | 37196079 |
| Pubmed | Human and mouse proteases: a comparative genomic approach. | USP17L7 USP17L4 USP17L2 USP17L1 USP17L6P USP17L3 USP17L15 USP17L8 | 8.76e-11 | 81 | 99 | 8 | 12838346 |
| Pubmed | DNA sequence and analysis of human chromosome 8. | USP17L7 USP17L4 USP17L1 CCN4 USP17L3 USP17L8 | 5.08e-09 | 48 | 99 | 6 | 16421571 |
| Pubmed | A Genome-Wide CRISPR Screen Identifies Genes Critical for Resistance to FLT3 Inhibitor AC220. | USP17L21 USP17L12 USP17L20 USP17L11 USP17L19 USP17L18 USP17L17 | 5.27e-08 | 119 | 99 | 7 | 28625976 |
| Pubmed | Embryonic demise caused by targeted disruption of a cysteine protease Dub-2. | USP17L2 USP17L15 USP17L13 | 8.93e-08 | 4 | 99 | 3 | 22984479 |
| Pubmed | Fibroblast and neutrophil collagenases cleave at two sites in the cartilage aggrecan interglobular domain. | ACAN MMP1 MMP7 | 7.77e-07 | 7 | 99 | 3 | 8216228 |
| Pubmed | Identification of Restriction Factors by Human Genome-Wide RNA Interference Screening of Viral Host Range Mutants Exemplified by Discovery of SAMD9 and WDR6 as Inhibitors of the Vaccinia Virus K1L-C7L- Mutant. | SAMD9 WDR6 | 8.02e-06 | 2 | 99 | 2 | 26242627 |
| Pubmed | The tumor suppressor Lgl1 regulates NMII-A cellular distribution and focal adhesion morphology to optimize cell migration. | LLGL2 LLGL1 | 8.02e-06 | 2 | 99 | 2 | 22219375 |
| Pubmed | The matrix metalloproteinase-7 and pro-enzyme of metalloproteinase-1 as a potential marker for patients with rectal cancer without distant metastasis. | MMP1 MMP7 | 8.02e-06 | 2 | 99 | 2 | 25549795 |
| Pubmed | Hugl1 and Hugl2 in mammary epithelial cells: polarity, proliferation, and differentiation. | LLGL2 LLGL1 | 8.02e-06 | 2 | 99 | 2 | 23110097 |
| Pubmed | [Change of matrix metalloproteinase-1 and matrix metalloproteinase-7 in serum and bronchoalveolar lavage fluid of patients with idiopathic pulmonary fibrosis and sarcoidosis]. | MMP1 MMP7 | 8.02e-06 | 2 | 99 | 2 | 20979817 |
| Pubmed | MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis. | MMP1 MMP7 | 8.02e-06 | 2 | 99 | 2 | 18447576 |
| Pubmed | Association between promoters polymorphisms of matrix metalloproteinases and risk of digestive cancers: a meta-analysis. | MMP1 MMP7 | 8.02e-06 | 2 | 99 | 2 | 23644699 |
| Pubmed | A novel type of myosin encoded by the mouse deafness gene shaker-2. | LLGL1 MYO15A | 8.02e-06 | 2 | 99 | 2 | 9703981 |
| Pubmed | Genetic polymorphisms in Matrix Metalloproteinases -1 and -7 and susceptibility to gastric cancer: an association study and meta-analysis. | MMP1 MMP7 | 8.02e-06 | 2 | 99 | 2 | 23893803 |
| Pubmed | Bladder cancer risk associated with genotypic polymorphism of the matrix metalloproteinase-1 and 7 in North Indian population. | MMP1 MMP7 | 8.02e-06 | 2 | 99 | 2 | 20826916 |
| Pubmed | Influence of matrix metalloproteinase gene polymorphisms in healthy North Indians compared to variations in other ethnic groups worldwide. | MMP1 MMP7 | 8.02e-06 | 2 | 99 | 2 | 20192597 |
| Pubmed | MMP1, 2, 3, 7, and 9 gene polymorphisms and urinary cancer risk: a meta-analysis. | MMP1 MMP7 | 2.40e-05 | 3 | 99 | 2 | 26301605 |
| Pubmed | No association between matrix metalloproteinase (MMP)-1, MMP-3, and MMP-7 SNPs and endometrial cancer risk. | MMP1 MMP7 | 2.40e-05 | 3 | 99 | 2 | 19435861 |
| Pubmed | Matrix metalloproteinase 7 (matrilysin) from human rectal carcinoma cells. Activation of the precursor, interaction with other matrix metalloproteinases and enzymic properties. | MMP1 MMP7 | 2.40e-05 | 3 | 99 | 2 | 7896811 |
| Pubmed | The association of matrix metalloproteinases polymorphisms and interleukins in advanced age-related macular degeneration. | MMP1 MMP7 | 2.40e-05 | 3 | 99 | 2 | 29947568 |
| Pubmed | E-cadherin and metalloproteinase-1 and -7 polymorphisms in colorectal cancer. | MMP1 MMP7 | 2.40e-05 | 3 | 99 | 2 | 19634113 |
| Pubmed | Association of matrix metalloproteinases 1, 7, and 9 gene polymorphisms with genetic susceptibility to colorectal carcinoma in a Han Chinese population. | MMP1 MMP7 | 2.40e-05 | 3 | 99 | 2 | 20662554 |
| Pubmed | Inhibition of hyaluronan synthases decreases matrix metalloproteinase-7 (MMP-7) expression and activity. | MMP7 HAS3 | 2.40e-05 | 3 | 99 | 2 | 19231585 |
| Pubmed | Expression of Matrix Metalloproteinases in Intraductal Papillary Mucinous Neoplasm of the Pancreas. | MMP1 MMP7 | 2.40e-05 | 3 | 99 | 2 | 31366549 |
| Pubmed | Genetic polymorphisms of MMP1, MMP3 and MMP7 gene promoter and risk of colorectal adenoma. | MMP1 MMP7 | 2.40e-05 | 3 | 99 | 2 | 17125518 |
| Pubmed | Polymorphism of Matrix Metalloproteinases Genes MMP1, MMP2, MMP3, and MMP7 and the Risk of Varicose Veins of Lower Extremities. | MMP1 MMP7 | 4.79e-05 | 4 | 99 | 2 | 28944430 |
| Pubmed | MMP expression in rheumatoid inflammation: the rs11568818 polymorphism is associated with MMP-7 expression at an extra-articular site. | MMP1 MMP7 | 4.79e-05 | 4 | 99 | 2 | 23343931 |
| Pubmed | Mammalian Lgl forms a protein complex with PAR-6 and aPKC independently of PAR-3 to regulate epithelial cell polarity. | LLGL2 LLGL1 | 4.79e-05 | 4 | 99 | 2 | 12725730 |
| Pubmed | FEV1 inversely correlates with metalloproteinases 1, 7, 9 and CRP in COPD by biomass smoke exposure. | MMP1 MMP7 | 4.79e-05 | 4 | 99 | 2 | 24980707 |
| Pubmed | Genetic and physical delineation of the region of the mouse deafness mutation shaker-2. | LLGL1 MYO15A | 4.79e-05 | 4 | 99 | 2 | 9168970 |
| Pubmed | [The protein expression difference of transforming growth factor beta1, matrix metalloproteinases 1,7,9 and tissue inhibitors of matrix metalloproteinases-1 between chronic rhinosinusitis, nasal polyps and normal mucosa tissues]. | MMP1 MMP7 | 4.79e-05 | 4 | 99 | 2 | 16248458 |
| Pubmed | Genetic polymorphisms of matrix metalloproteinases: susceptibility and prognostic implications for prostate cancer. | MMP1 MMP7 | 4.79e-05 | 4 | 99 | 2 | 19303106 |
| Pubmed | Genetic variants in matrix metalloproteinase genes are associated with development of gastric ulcer in H. Pylori infection. | MMP1 MMP7 | 4.79e-05 | 4 | 99 | 2 | 16405530 |
| Pubmed | Polymorphisms in the promoter regions of the matrix metalloproteinases-1, -3, -7, and -9 and the risk of epithelial ovarian cancer in China. | MMP1 MMP7 | 4.79e-05 | 4 | 99 | 2 | 16278009 |
| Pubmed | Simulated physiological stretch-induced proliferation of human bladder smooth muscle cells is regulated by MMPs. | MMP1 MMP7 | 4.79e-05 | 4 | 99 | 2 | 25263962 |
| Pubmed | Expression spectra of matrix metalloproteinases in metastatic non-small cell lung cancer. | MMP1 MMP7 | 4.79e-05 | 4 | 99 | 2 | 15375490 |
| Pubmed | Role of MMP-1 (-519A/G, -1607 1G/2G), MMP-3 (Lys45Glu), MMP-7 (-181A/G), and MMP-12 (-82A/G) Variants and Plasma MMP Levels on Obesity-Related Phenotypes and Microvascular Reactivity in a Tunisian Population. | MMP1 MMP7 | 4.79e-05 | 4 | 99 | 2 | 29317790 |
| Pubmed | Matrix metalloproteinases and genetic mouse models in cancer research: a mini-review. | MMP1 MMP7 | 4.79e-05 | 4 | 99 | 2 | 25352026 |
| Pubmed | E3 ubiquitin ligase RNF123 targets lamin B1 and lamin-binding proteins. | USP17L7 USP17L12 OBSCN DNAH2 MUC19 KIAA1671 CCN4 USP17L3 EIF3A MTCL1 | 4.85e-05 | 736 | 99 | 10 | 29676528 |
| Pubmed | Membrane-type 1 MMP (MMP-14) cleaves at three sites in the aggrecan interglobular domain. | ACAN MMP1 | 7.98e-05 | 5 | 99 | 2 | 9688535 |
| Pubmed | Association of genotypes at the matrix metalloproteinase (MMP) loci with carotid IMT and presence of carotid and femoral atherosclerotic plaques. | MMP1 MMP7 | 7.98e-05 | 5 | 99 | 2 | 24043512 |
| Pubmed | Expression of metalloproteinases 1, 2, 7, 9, and 12 in human cytotrophoblastic cells from normal and preeclamptic placentas. | MMP1 MMP7 | 7.98e-05 | 5 | 99 | 2 | 22936257 |
| Pubmed | Matrix metalloproteinase haplotypes associated with coronary artery aneurysm formation in patients with Kawasaki disease. | MMP1 MMP7 | 7.98e-05 | 5 | 99 | 2 | 20827277 |
| Pubmed | Variation in the matrix metalloproteinase-3, -7, -12 and -13 genes is associated with functional status in rheumatoid arthritis. | MMP1 MMP7 | 7.98e-05 | 5 | 99 | 2 | 17373931 |
| Pubmed | Nitric oxide-mediated invasion in Barrett's high-grade dysplasia and adenocarcinoma. | MMP1 MMP7 | 7.98e-05 | 5 | 99 | 2 | 20584750 |
| Pubmed | Matrix metalloproteinases: structures, evolution, and diversification. | MMP1 MMP7 | 7.98e-05 | 5 | 99 | 2 | 9737711 |
| Pubmed | Matrix metalloproteinase single-nucleotide polymorphisms and haplotypes predict breast cancer progression. | MMP1 MMP7 | 1.19e-04 | 6 | 99 | 2 | 18006768 |
| Pubmed | Neutrophil collagenase (MMP-8) cleaves at the aggrecanase site E373-A374 in the interglobular domain of cartilage aggrecan. | ACAN MMP1 | 1.19e-04 | 6 | 99 | 2 | 7998967 |
| Pubmed | Single nucleotide polymorphisms in matrix metalloproteinase genes and lung cancer chemotherapy response and prognosis. | MMP1 MMP7 | 1.19e-04 | 6 | 99 | 2 | 19643940 |
| Pubmed | Putative functional polymorphisms of MMP9 predict survival of NSCLC in a Chinese population. | MMP1 MMP7 | 1.19e-04 | 6 | 99 | 2 | 19132754 |
| Pubmed | The effect of epidermal growth factor on matrix metalloproteinases and tissue inhibitors of metalloproteinase gene expression in cultured human gingival fibroblasts. | MMP1 MMP7 | 1.19e-04 | 6 | 99 | 2 | 17181997 |
| Pubmed | Expression of matrix metalloproteinases in ovarian endometriomas: immunohistochemical study and enzyme immunoassay. | MMP1 MMP7 | 1.19e-04 | 6 | 99 | 2 | 12034345 |
| Pubmed | ADAMTS1 cleaves aggrecan at multiple sites and is differentially inhibited by metalloproteinase inhibitors. | ACAN MMP1 | 1.19e-04 | 6 | 99 | 2 | 12054629 |
| Pubmed | Fine physical mapping of the human matrix metalloproteinase genes clustered on chromosome 11q22.3. | MMP1 MMP7 | 1.67e-04 | 7 | 99 | 2 | 8921407 |
| Pubmed | Matrix metalloproteinases 19 and 20 cleave aggrecan and cartilage oligomeric matrix protein (COMP). | ACAN MMP1 | 1.67e-04 | 7 | 99 | 2 | 10922468 |
| Pubmed | Matrix metalloproteinases cleave tissue factor pathway inhibitor. Effects on coagulation. | MMP1 MMP7 | 1.67e-04 | 7 | 99 | 2 | 10859319 |
| Pubmed | Functional polymorphisms and haplotypes in the promoter of the MMP2 gene are associated with risk of nasopharyngeal carcinoma. | MMP1 MMP7 | 1.67e-04 | 7 | 99 | 2 | 17607721 |
| Pubmed | Expression of matrix metalloproiteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) in hepatocellular carcinoma tissue, compared with the surrounding non-tumor tissue. | MMP1 MMP7 | 1.67e-04 | 7 | 99 | 2 | 17564313 |
| Pubmed | Matrix remodeling by MMPs during wound repair. | MMP1 MMP7 | 1.67e-04 | 7 | 99 | 2 | 25770908 |
| Pubmed | Characterization of opticin digestion by proteases involved in osteoarthritis development. | MMP1 MMP7 | 2.22e-04 | 8 | 99 | 2 | 23845380 |
| Pubmed | Polarity protein complex Scribble/Lgl/Dlg and epithelial cell barriers. | LLGL2 LLGL1 | 2.22e-04 | 8 | 99 | 2 | 23397623 |
| Pubmed | Regulatory polymorphisms in extracellular matrix protease genes and susceptibility to rheumatoid arthritis: a case-control study. | MMP1 MMP7 | 2.22e-04 | 8 | 99 | 2 | 16356191 |
| Pubmed | Brevican is degraded by matrix metalloproteinases and aggrecanase-1 (ADAMTS4) at different sites. | MMP1 MMP7 | 2.85e-04 | 9 | 99 | 2 | 10986281 |
| Pubmed | A dual-activity topoisomerase complex regulates mRNA translation and turnover. | B4GALNT4 RAPGEF6 MORN1 SZT2 OBSCN CARD10 C6orf132 ARHGEF40 LLGL2 ATG9A HAS3 | 3.12e-04 | 1105 | 99 | 11 | 35748872 |
| Pubmed | Interactomes of Glycogen Synthase Kinase-3 Isoforms. | RAPGEF6 KIAA1671 ALMS1 EIF3A MTCL1 | 3.38e-04 | 209 | 99 | 5 | 36779422 |
| Pubmed | Systematic bromodomain protein screens identify homologous recombination and R-loop suppression pathways involved in genome integrity. | BRWD3 KIAA1671 FCSK ZNF469 ARHGEF40 FXR1 ALMS1 WDR6 BRD7 TAF5 PHIP | 3.39e-04 | 1116 | 99 | 11 | 31753913 |
| Cytoband | 4p16.1 | USP17L21 USP17L12 USP17L20 USP17L11 USP17L24 USP17L5 USP17L10 USP17L19 USP17L18 USP17L17 USP17L6P USP17L22 USP17L15 USP17L13 | 2.00e-23 | 79 | 99 | 14 | 4p16.1 |
| Cytoband | Ensembl 112 genes in cytogenetic band chr4p16 | USP17L21 USP17L12 USP17L20 USP17L11 USP17L24 USP17L5 USP17L10 USP17L19 USP17L18 USP17L17 USP17L6P USP17L22 USP17L15 USP17L13 | 6.68e-17 | 222 | 99 | 14 | chr4p16 |
| Cytoband | 8p23.1 | USP17L7 FAM86B1 USP17L4 USP17L2 USP17L1 USP17L3 USP17L8 | 4.79e-08 | 154 | 99 | 7 | 8p23.1 |
| Cytoband | Ensembl 112 genes in cytogenetic band chr8p23 | USP17L7 FAM86B1 USP17L4 USP17L2 USP17L1 USP17L3 USP17L8 | 8.17e-07 | 234 | 99 | 7 | chr8p23 |
| Cytoband | 16q22.1 | B3GNT9 FCSK HAS3 | 1.78e-03 | 110 | 99 | 3 | 16q22.1 |
| Cytoband | 2p16.1 | PEX13 PPP4R3B | 2.19e-03 | 32 | 99 | 2 | 2p16.1 |
| GeneFamily | WD repeat domain containing | GRWD1 DCAF8L2 DYNC2I1 BRWD3 LLGL2 LLGL1 WDR6 WDR87 TAF5 PHIP DYNC1I2 | 4.02e-10 | 262 | 56 | 11 | 362 |
| GeneFamily | Membrane associated guanylate kinases|PDZ domain containing|Scribble complex | LLGL2 LLGL1 | 5.63e-05 | 4 | 56 | 2 | 1224 |
| GeneFamily | StAR related lipid transfer domain containing | ACOT12 STARD9 | 9.64e-04 | 15 | 56 | 2 | 759 |
| GeneFamily | Endogenous ligands|Matrix metallopeptidases | MMP1 MMP7 | 2.49e-03 | 24 | 56 | 2 | 891 |
| Coexpression | MADAN_DPPA4_TARGETS | USP17L7 USP17L21 USP17L4 USP17L2 USP17L12 USP17L1 USP17L20 USP17L11 USP17L5 USP17L10 USP17L19 USP17L18 USP17L17 USP17L6P USP17L3 USP17L22 USP17L15 USP17L8 USP17L13 | 5.35e-29 | 86 | 98 | 19 | MM1312 |
| Coexpression | GRAESSMANN_RESPONSE_TO_MC_AND_SERUM_DEPRIVATION_DN | USP17L7 USP17L21 USP17L4 USP17L2 USP17L12 USP17L1 USP17L20 USP17L11 USP17L5 USP17L10 USP17L19 USP17L18 USP17L17 USP17L6P USP17L3 USP17L22 USP17L15 USP17L8 USP17L13 | 1.27e-26 | 112 | 98 | 19 | MM1095 |
| Coexpression | GERY_CEBP_TARGETS | USP17L7 USP17L21 USP17L4 USP17L2 USP17L12 USP17L1 USP17L20 USP17L11 USP17L5 USP17L10 USP17L19 USP17L18 USP17L17 USP17L6P USP17L3 USP17L22 USP17L15 USP17L8 USP17L13 | 1.62e-23 | 160 | 98 | 19 | MM1155 |
| Coexpression | GRAESSMANN_RESPONSE_TO_MC_AND_DOXORUBICIN_UP | USP17L7 USP17L21 USP17L4 USP17L2 USP17L12 USP17L1 USP17L20 USP17L11 USP17L5 USP17L10 USP17L19 C6orf132 CAPN10 USP17L18 USP17L17 USP17L6P USP17L3 ARHGAP27 USP17L22 USP17L15 USP17L8 USP17L13 | 2.33e-15 | 647 | 98 | 22 | MM981 |
| Coexpression | MARSON_BOUND_BY_FOXP3_STIMULATED | USP17L7 USP17L21 USP17L4 TTC24 USP17L2 USP17L12 USP17L1 USP17L20 USP17L11 ETV3 DYNC2I1 USP17L5 CHD1 USP17L10 USP17L19 USP17L18 USP17L17 WDR6 USP17L6P USP17L3 USP17L22 USP17L15 USP17L8 USP17L13 | 9.50e-13 | 1072 | 98 | 24 | MM1031 |
| Coexpression | GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_UP | USP17L7 USP17L21 USP17L4 USP17L2 USP17L12 USP17L1 USP17L20 USP17L11 USP17L5 USP17L10 USP17L19 C6orf132 CAPN10 USP17L18 CCN4 USP17L17 PTRH1 USP17L6P USP17L3 ARHGAP27 USP17L22 USP17L15 USP17L8 USP17L13 | 1.59e-11 | 1226 | 98 | 24 | MM979 |
| Coexpression | BRUINS_UVC_RESPONSE_LATE | USP17L7 FAM86B1 USP17L21 USP17L4 USP17L2 USP17L12 USP17L1 USP17L20 USP17L11 USP17L5 USP17L10 USP17L19 USP17L18 FXR1 PLXDC2 USP17L17 USP17L6P USP17L3 ARHGAP27 USP17L22 USP17L15 USP17L8 USP17L13 | 6.76e-11 | 1198 | 98 | 23 | MM1062 |
| ToppCell | Entopeduncular-Endothelial-ENDOTHELIAL_STALK-Flt1_1-Endothelial_Stalk.Flt1.Car4_(Car4)--|Entopeduncular / BrainAtlas - Mouse McCarroll V32 | MUC19 C6orf132 WDR87 ALPK2 | 1.35e-05 | 70 | 92 | 4 | 2121ba6a0beb2a8fdc589ff1063e7d8c2c3c68f6 |
| ToppCell | Entopeduncular-Endothelial-ENDOTHELIAL_STALK-Flt1_1-Endothelial_Stalk.Flt1.Car4_(Car4)-|Entopeduncular / BrainAtlas - Mouse McCarroll V32 | MUC19 C6orf132 WDR87 ALPK2 | 1.35e-05 | 70 | 92 | 4 | cd6bca68fe52f451716fc8c0b1745984bc9ec057 |
| ToppCell | Entopeduncular-Endothelial-ENDOTHELIAL_STALK-Flt1_1-Endothelial_Stalk.Flt1.Car4_(Car4)|Entopeduncular / BrainAtlas - Mouse McCarroll V32 | MUC19 C6orf132 WDR87 ALPK2 | 1.35e-05 | 70 | 92 | 4 | be300c0447735aba89df4c3082b81eb5abf22770 |
| ToppCell | Basal_cells-IPF_03|World / lung cells shred on cell class, cell subclass, sample id | SERPINF1 ACAN MMP1 MMP7 HAS3 | 2.59e-05 | 168 | 92 | 5 | 48089fa2d4a0f31a72405717119b767a92571f01 |
| ToppCell | PND14-Mesenchymal-Mesenchymal_structural-Fibroblastic-AF2|PND14 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | B3GNT9 SERPINF1 LGI4 ZNF469 PLXDC2 | 3.69e-05 | 181 | 92 | 5 | 3462aa1c08fbaf613b6278ab2c7a5a0940bf537d |
| ToppCell | PND14-Mesenchymal-Mesenchymal_structural-Fibroblastic-AF2-AF2_mature|PND14 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | B3GNT9 SERPINF1 LGI4 ZNF469 PLXDC2 | 3.69e-05 | 181 | 92 | 5 | 6730e249cac55ae892cc567d9211615882f3dab4 |
| ToppCell | P07-Mesenchymal-mesenchymal_fibroblast-mesenchymal_alveolar_niche_cell|P07 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase | B3GNT9 SERPINF1 CCN4 ZNF469 PLXDC2 | 3.99e-05 | 184 | 92 | 5 | 01257e5c12e38b849fd3d9496c43ded666249ba5 |
| ToppCell | PCW_07-8.5-Endothelial-Endothelial_mature-endo_arterial_(9)|PCW_07-8.5 / Celltypes from embryonic and fetal-stage human lung | MUC19 CARD10 KIAA1671 DHH ARHGAP27 | 4.65e-05 | 190 | 92 | 5 | 1307688255a1250fa300edf2c41f1affe31dcc98 |
| ToppCell | Monocytes-Tissue-resident_macrophages|World / Immune cells in Kidney/Urine in Lupus Nephritis | SERPINF1 CHKA ARHGEF40 PLXDC2 MRC2 | 4.65e-05 | 190 | 92 | 5 | 07215e8f292cb54c670037aaf28393cddbe5548c |
| ToppCell | IPF-Myeloid-cDC2|World / Disease state, Lineage and Cell class | SERPINF1 ETV3 CHKA PLXDC2 HERPUD1 | 4.77e-05 | 191 | 92 | 5 | 9fda87fb6bc5b8b6c0214ec909ebbc9f3f65319b |
| ToppCell | droplet-Limb_Muscle-nan-18m-Mesenchymal-chondrocyte-like|Limb_Muscle / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | SERPINF1 CCN4 PLXDC2 MRC2 CHRDL1 | 5.39e-05 | 196 | 92 | 5 | fcb275746bf51269ed8ba4cf93edb054a45f1ccd |
| ToppCell | LPS_anti-TNF-Epithelial_alveolar-AT_1-Differentiating_AT2|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type | CHKA LLGL2 MTCL1 MMP7 PHIP | 5.52e-05 | 197 | 92 | 5 | 3d13a4f2e86422900ee2194e8a1fd1cf9750d5d3 |
| ToppCell | droplet-Limb_Muscle-MUSCLE-30m-Mesenchymal-chondrocyte-like|Limb_Muscle / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | SERPINF1 CHD1 CCN4 PLXDC2 CHRDL1 | 5.52e-05 | 197 | 92 | 5 | cfd4cc5fb8d7a60dd5c0d2a1a7bad7ba38c19d40 |
| ToppCell | droplet-Limb_Muscle-nan-3m-Mesenchymal-chondrocyte-like|Limb_Muscle / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | SERPINF1 CCN4 PLXDC2 MRC2 CHRDL1 | 5.79e-05 | 199 | 92 | 5 | edd5300da1a3b758210ff8f949e9d1988b8bc7e2 |
| ToppCell | Control_saline-Mesenchymal_fibroblastic|Control_saline / Treatment groups by lineage, cell group, cell type | B3GNT9 SERPINF1 CCN4 PLXDC2 MRC2 | 5.93e-05 | 200 | 92 | 5 | 64ae5cf6cb4fc94cf1052abd82648f6b8e6445fe |
| ToppCell | mild|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class | SAMD9 CHD1 BRD7 EIF3A PHIP | 5.93e-05 | 200 | 92 | 5 | 12f1685ce8f218433068e090c9d839cd5a1910bf |
| ToppCell | Fetal_brain-organoid_Tanaka_cellReport-GW12-Mesenchymal-Unfolded_protein_responsible_cell|GW12 / Sample Type, Dataset, Time_group, and Cell type. | SERPINF1 OBSCN DNAH2 CHKA CHRDL1 | 5.93e-05 | 200 | 92 | 5 | 6b7314c425f6b40f1301dd39cc02b0436e96a2ec |
| ToppCell | Control_saline-Mesenchymal_fibroblastic-Fibroblasts|Control_saline / Treatment groups by lineage, cell group, cell type | B3GNT9 SERPINF1 CCN4 PLXDC2 MRC2 | 5.93e-05 | 200 | 92 | 5 | a1fc74c1b27e104895910bc7cdce7ba33d30df7e |
| ToppCell | Brain_organoid-organoid_Tanaka_cellReport-1m-Neuronal-Interneuron|1m / Sample Type, Dataset, Time_group, and Cell type. | CHGB BRWD3 CHRNB2 PGBD5 DYNC1I2 | 5.93e-05 | 200 | 92 | 5 | fc839e9c33ea1d4ee0f42f21fd32a54e7cbe1f5a |
| ToppCell | Tracheal-NucSeq-Stromal-Fibroblastic-Fibro_adventitial|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | SERPINF1 PLXDC2 MRC2 STARD9 CHRDL1 | 5.93e-05 | 200 | 92 | 5 | 0c25d56292b9e5fefa4521b72635449be1ffd6fe |
| ToppCell | Fetal_brain-organoid_Tanaka_cellReport-GW12-Mesenchymal|GW12 / Sample Type, Dataset, Time_group, and Cell type. | SERPINF1 OBSCN DNAH2 CHKA CHRDL1 | 5.93e-05 | 200 | 92 | 5 | be83f442179ba4217d12f0458059586ff3130991 |
| Disease | primary ovarian insufficiency (implicated_via_orthology) | USP17L7 USP17L21 USP17L4 USP17L2 USP17L12 USP17L1 USP17L20 USP17L11 USP17L24 USP17L5 USP17L10 USP17L19 USP17L18 USP17L17 USP17L6P USP17L3 USP17L22 USP17L15 USP17L8 USP17L13 | 6.96e-39 | 46 | 94 | 20 | DOID:5426 (implicated_via_orthology) |
| Disease | congenital heart disease (implicated_via_orthology) | USP17L7 USP17L21 USP17L4 USP17L2 USP17L12 USP17L1 USP17L20 USP17L11 USP17L24 USP17L5 USP17L10 USP17L19 USP17L18 USP17L17 USP17L6P USP17L3 USP17L22 USP17L15 USP17L8 USP17L13 | 1.36e-34 | 69 | 94 | 20 | DOID:1682 (implicated_via_orthology) |
| Disease | neuroblastoma (implicated_via_orthology) | LLGL2 LLGL1 | 9.98e-05 | 5 | 94 | 2 | DOID:769 (implicated_via_orthology) |
| Disease | degenerative disc disease (implicated_via_orthology) | ACAN MMP1 | 2.09e-04 | 7 | 94 | 2 | DOID:90 (implicated_via_orthology) |
| Disease | kidney cancer (implicated_via_orthology) | LLGL2 LLGL1 | 5.42e-04 | 11 | 94 | 2 | DOID:263 (implicated_via_orthology) |
| Disease | aspartate aminotransferase measurement | RAPGEF6 OBSCN DNAH2 MUC19 CHKA MYO15A HERPUD1 PHIP ALPK2 | 2.38e-03 | 904 | 94 | 9 | EFO_0004736 |
| Disease | beverage consumption measurement | MKRN2OS SIM1 DYNC1I2 | 2.39e-03 | 83 | 94 | 3 | EFO_0010088 |
| Disease | Intellectual Disability | LGI4 BRWD3 CAPN10 FCSK PHIP DYNC1I2 | 3.10e-03 | 447 | 94 | 6 | C3714756 |
| Disease | brain cancer (implicated_via_orthology) | LLGL2 LLGL1 | 3.10e-03 | 26 | 94 | 2 | DOID:1319 (implicated_via_orthology) |
| Disease | obesity (is_implicated_in) | SERPINF1 SIM1 CAPN10 | 3.11e-03 | 91 | 94 | 3 | DOID:9970 (is_implicated_in) |
